For the Inventor, By the Inventor

Enter assignee name

La Chaux-de-Fonds, Switzerland

Glenmark Specialty S.a.

USPTO Granted Patents = 24

CIPO Patents = 4

EPO Patents = 4

Trademarks = 8

Forward Citations = 43

Loading Chart...

Loading Chart...

29 inventors (with patents filed for the assignee):

Ulhas R Dhuppad (15 out of 21 patents)

Chandrakant Dhatrak (14 out of 15 patents)

Neelima Khairatkar-Joshi (9 out of 44 patents)

4. Abhay Kulkarni (9 out of 11 patents)

5. Piyush Agarwal (9 out of 9 patents)

6. Patrick Keohane (9 out of 9 patents)

7. Sudeesh K Tantry (9 out of 9 patents)

8. Chad Oh (9 out of 9 patents)

9. Ashok Katkurwar (9 out of 10 patents)

10. Rajesh Ankam (9 out of 10 patents)

11. Yashwant Gupta (9 out of 10 patents)

12. Vikram Mansingh Bhosale (9 out of 11 patents)

13. Dinesh Pradeep Wale (7 out of 8 patents)

14. Franciscus Koppenhagen (6 out of 7 patents)

15. Sunil Chaudhari (5 out of 7 patents)

24 patents: Sort by Forward Citations

1. 12303635 - Dispensing device and pharmaceutical composition for the treatment of rhinitis (2025-05-20),

2. 12064442 - Treatment of allergic rhinitis using a combination of mometasone and olopatadine (2024-08-20),

3. 11679210 - Dispensing device and pharmaceutical composition for the treatment of rhinitis (2023-06-20),

4. 11400101 - Treatment of allergic rhinitis using a combination of mometasone and olopatadine (2022-08-02),

5. 10765686 - Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine (2020-09-08),

6. 10758550 - Treatment of allergic rhinitis using a combination of mometasone and olopatadine (2020-09-01),

7. 10653683 - Tiotropium inhalation solution for nebulization (2020-05-19),

8. 10653661 - Treatment of allergic rhinitis using a combination of mometasone and olopatadine (2020-05-19),

9. 10646500 - Treatment of allergic rhinitis using a combination of mometasone and olopatadine (2020-05-12),

10. 10632109 - Tiotropium inhalation solution for nebulization (2020-04-28),

11. 10632108 - Tiotropium inhalation solution for nebulization (2020-04-28),

12. 10561672 - Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine (2020-02-18),

13. 10555903 - Nebulizable compositions of tiotropium and formoterol (2020-02-11),

14. 10548907 - Treatment of allergic rhinitis using a combination of mometasone and olopatadine (2020-02-04),

15. 10517880 - Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine (2019-12-31),

Glenmark Specialty S.A. is a global pharmaceutical company specializing in the research, development, and manufacturing of innovative medicines. With a focus on providing affordable healthcare solutions, Glenmark offers a wide range of pharmaceutical products across various therapeutic areas. The company is committed to improving patient outcomes and contributing to the well-being of communities worldwide.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 2 2025

24 Patents

#6 in La Chaux-de-Fonds

#512 in Switzerland

#25,806 in the World

La Chaux-de-Fonds, Switzerland

Glenmark Specialty S.a.

Forward Citations = 43

29 inventors:

Ulhas R Dhuppad (15 out of 21 patents)

Chandrakant Dhatrak (14 out of 15 patents)

Neelima Khairatkar-Joshi (9 out of 44 patents)

4. Abhay Kulkarni (9 out of 11 patents)

5. Piyush Agarwal (9 out of 9 patents)

Please report any incorrect information to support@idiyas.com

Loading…